Company Submitted Best Overall Concept, Paving
Way to Establish Local Production
TSX | NYSE: ACB
EDMONTON, April 5, 2019 /CNW/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today
that the Company has been selected by the German Bundesinstitut für
Arzneimittel und Medizinprodukte BfArM (Federal Institute for Drugs
and Medical Devices) as one of three winners in the public tender
to cultivate and distribute medical cannabis in Germany. The contract will be formalized at
the earliest on April 17, 2019,
pending the outcome of an appeal procedure on which a ruling is
anticipated by April 10, 2019.
The tender saw 79 companies participating, with the
winners able to establish production in Germany upon the completion of the contract
associated with the tender. The selection process was based on the
submission of a concept for domestic cannabis production, delivery
and pricing. Aurora's concept, judged on criteria such as facility
design, quality, security and logistics, received the highest
ranking out of all concepts submitted, validating the Company's
leadership in integrated cultivation, production and delivery.
The Company was awarded the maximum number of 5 of the 13 lots
in the tender over a period of four years with a minimum supply of
4000kg total. The cannabis produced will be sold to the German
government and supplied to wholesalers for distribution to
pharmacies.
"We are very proud to have been selected as one of only three
companies by the German government, which is a great achievement by
our team," said Neil Belot, Chief
Global Business Development Officer. "Having the highest rated
concept is a strong validation of the Aurora Standard cultivation
philosophy, as well as of our track record in the delivery of safe
and high-quality medical cannabis products to the German system. We
commenced delivering dried cannabis flower from Canada to the German market in 2017, and
recently added cannabis extracts to our offerings for German
patients. Winning the tender reflects a natural evolution for
Aurora, establishing a more prominent local footprint in this
important international market with over 82 million people."
Dr. Florian Holzapfel of Aurora
Deutschland GmbH, added, "Being one of the winners in this tender
reflects our ability to work with international governments and
establish ourselves as a trusted partner in multiple global
jurisdictions. Upon finalization of the allotment we will commence
with our project to construct a state-of-the-art cannabis
production facility to further service German patients with safe,
high-quality cannabis."
Facility
The Company's concept focused on the construction of a highly
secure, state-of-the-art, EU GMP compliant indoor cultivation
facility with flexibility for future growth. The new facility will
be located at the industrial park in Leuna, Saxony Anhalt, near
Leipzig. The Leuna industrial park
provides all required industrial and logistical infrastructure
required for the operation of the facility, with a considerable
labour market to draw from. The facility is designed to have
capacity in excess of the tendered amounts to provide flexibility
in meeting future growth.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 500,000 kg per
annum and sales and operations in 24 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high quality product at low cost. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet EU GMP standards, and its
first production facility, the recently acquired MedReleaf Markham
facility, and its wholly owned European medical cannabis
distributor Aurora Deutschland have achieved this level of
certification.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 15 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela,
and ICC Labs – Aurora is distinguished by its reputation as a
partner and employer of choice in the global cannabis sector,
having invested in and established strategic partnerships with a
range of leading innovators, including: Radient Technologies Inc.
(TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group
Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom
Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty
Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC:
CTTH), Alcanna Inc. (TSX: CLIQ) and High Tide Inc. (CSE:HITI).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Neither the TSX, NYSE nor their Regulation Services Provider
(as that term is defined in the policies of the TSX and NYSE)
accepts responsibility for the adequacy or accuracy of this
release.
Terry Booth, CEO
Aurora Cannabis Inc.
Forward-Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"), including, but not
limited to, statements with respect to the performance of the
Company. Forward-looking statements are frequently characterized by
words such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur, and include, but are
not limited to statements regarding the formalization of the
contract associated with the tender, the outcome of the
appeal procedure, the construction and completion of the
Company's production facility in Germany, and the
production capacity of the facility. These statements are only
predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-awarded-maximum-number-of-lots-in-german-cannabis-production-tender-300825316.html
SOURCE Aurora Cannabis Inc.